Asparagine synthetase: a new potential biomarker in ovarian cancer.

L-Asparaginase (L-ASP) is an enzyme drug that has been an asset to leukemia treatment regimens for four decades. Variability in its clinical efficacy, however, has prompted the search for biomarkers capable of distinguishing responders from non-responders. In that regard, the NCI-60 cell line panel has served as a biomarker discovery platform and has led to the identification of a correlation between L-ASP efficacy and asparagine synthetase (ASNS) expression in cultured cells. The presence of that correlation in the ovarian subpanel of the NCI-60 has made a case for repositioning L-ASP to ovarian cancer. This review presents an overview of the biomarker development process, summarizes the efforts that have been invested thus far in developing ASNS as a biomarker for ovarian cancer treatment, highlights the role of RNAi and the limitations of the NCI-60 in that process, and addresses important considerations for next steps in the development of ASNS as a predictive biomarker.

[1]  F. Dieterle,et al.  Biomarkers in oncology drug development: rescuers or troublemakers? , 2008, Expert opinion on drug metabolism & toxicology.

[2]  Holly Janes,et al.  Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.

[3]  J. Weinstein,et al.  Asparagine synthetase is a predictive biomarker of l-asparaginase activity in ovarian cancer cell lines , 2008, Molecular Cancer Therapeutics.

[4]  Martin Widschwendter,et al.  HOXA11 DNA methylation—A novel prognostic biomarker in ovarian cancer , 2008, International journal of cancer.

[5]  R. Kaufman,et al.  MEK Signaling Is Required for Phosphorylation of eIF2α following Amino Acid Limitation of HepG2 Human Hepatoma Cells* , 2008, Journal of Biological Chemistry.

[6]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[7]  R. Zeillinger,et al.  Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer , 2008, Clinical Cancer Research.

[8]  Lilya V. Matyunina,et al.  Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas , 2007, PloS one.

[9]  K. Nakao,et al.  Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. , 2007, Kidney international.

[10]  Jae K. Lee,et al.  Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study , 2007, Molecular Cancer Therapeutics.

[11]  J. Wagner,et al.  Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs , 2007, Clinical pharmacology and therapeutics.

[12]  Gabriel S. Eichler,et al.  Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells , 2006, Molecular Cancer Therapeutics.

[13]  John N. Weinstein,et al.  Spotlight on molecular profiling: “Integromic” analysis of the NCI-60 cancer cell lines , 2006, Molecular Cancer Therapeutics.

[14]  D. Durden,et al.  Role of Glutamine Depletion in Directing Tissue-specific Nutrient Stress Responses to L-Asparaginase* , 2006, Journal of Biological Chemistry.

[15]  Liz Y. Han,et al.  Circulating cell-free DNA: A novel biomarker for response to therapy in ovarian carcinoma , 2006, Cancer biology & therapy.

[16]  R. Shoemaker.  The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[17]  R. Shah,et al.  Can pharmacogenetics help rescue drugs withdrawn from the market? , 2006, Pharmacogenomics.

[18]  William C Reinhold,et al.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.

[19]  G. Hortobagyi,et al.  Pharmacogenomics and clinical biomarkers in drug discovery and development. , 2005, American journal of clinical pathology.

[20]  Daniel J Sargent,et al.  Clinical trial designs for predictive marker validation in cancer treatment trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Cope,et al.  Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis: A Mutational Analysis With Immunohistochemical Correlation , 2005, The American journal of surgical pathology.

[22]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[23]  S. Holbeck,et al.  Update on NCI in vitro drug screen utilities. , 2004, European journal of cancer.

[24]  S. Kimball,et al.  The GCN2 eIF2α Kinase Is Required for Adaptation to Amino Acid Deprivation in Mice , 2002, Molecular and Cellular Biology.

[25]  I. Tannock,et al.  Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.

[26]  G. Guidotti,et al.  Glutamine deprivation-mediated cell shrinkage induces ligand-independent CD95 receptor signaling and apoptosis , 2001, Cell Death and Differentiation.

[27]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[28]  R. Sood,et al.  A mammalian homologue of GCN2 protein kinase important for translational control by phosphorylation of eukaryotic initiation factor-2alpha. , 2000, Genetics.

[29]  G. Viale,et al.  The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  M. Boyd,et al.  Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen , 1995 .

[31]  H. Mikawa,et al.  The Inhibition of Lymphocyte Blastogenesis by Asparaginase: Critical Role of Glutamine in both T and B Lymphocyte Transformation , 1992, Acta paediatrica Japonica : Overseas edition.

[32]  M. Corada,et al.  L-asparaginase effects on inhibition of protein synthesis and lowering of the glutamine content in cultured rat hepatocytes. , 1986, Toxicology letters.

[33]  A. Bendich,et al.  Enzyme-induced asparagine and glutamine depletion and immune system function. , 1983, The American journal of clinical nutrition.

[34]  A. Meister,et al.  Glutamine-dependent asparagine synthetase from leukemia cells. Chloride dependence, mechanism of action, and inhibition. , 1972, The Journal of biological chemistry.

[35]  L. Levintow.  Evidence that glutamine is a precursor of asparagine in a human cell in tissue culture. , 1957, Science.

[36]  D. Covell.  Connecting chemosensitivity, gene expression and disease. , 2008, Trends in pharmacological sciences.

[37]  Liz Y. Han,et al.  Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. , 2007, Cancer research.

[38]  R. Sood,et al.  A Mammalian Homologue of GCN 2 Protein Kinase Important for Translational Control by Phosphorylation of Eukaryotic Initiation Factor-2 a , 2000 .